Generic Cos. Tell Fed. Circ. Not To Halt PTAB Restasis IPRs
The Patent Trial and Appeal Board should be allowed to proceed with its review of patents covering Allergan PLC's Restasis medication, generic-drug makers said Friday, urging the Federal Circuit not to...To view the full article, register now.
Already a subscriber? Click here to view full article